Highlights of the 6th Annual Community Oncology Conference

A CME-Certified Supplement to Community Oncology (R), supported by educational grants from Bristol-Myers Squibb, Cephalon, Genentech, OSI Pharmaceuticals, Inc, Pfizer. This is activity is also supported, in part, by an educational donation provided by: Amgen Oncology. This activity is jointly sponsored by Boston University School of Medicine and Global Academy for Medical Education.

• Topic Highlights
• Faculty/Faculty Disclosure Statement
• Target Audience
• Educational Needs
• Learning Objectives
• Accreditation Statement
• Credit Designation
• Link to post-test and evaluation

Click here to download ( PDF - 1.05MB)

 

 

Topic Highlights

• Novel Her-2-neu Targeted Agents
• GI and Colon Cancer
• ASH Review Part 2:Lymphoma Therapy
• Advanced Non-Small Cell Lung Cancer: Treatment and Outcomes
• Melanoma: Clinical Trials and New Advances
• PARP Inhibitors in the Treatment of Breast Cancer
• Recent Therapeutic Developments for Castration-Resistant Prostate Cancer
• Current Status of Bone-Targeted Therapy for Cancer Patients

Faculty/Faculty Disclosure Statement

Lee S. Schwartzberg, MD, chair

Medical Director - The West Clinic

Clinical Professor of Medicine - University of Tennessee College of Medicine

Memphis, Tennessee

Author has nothing to disclose.

Author indicates that he does not plan to discuss unlabeled/investigational uses of commercial products.

Jame Abraham, MD

Bonnie Wells Wilson Distinguished Professor and Eminent Scholar

West Virginia University

Morgantown, West Virginia

Author has been a consultant for Genentech.

Author indicates that he does plan to discuss unlabeled/investigational uses of commercial products.

Axel Grothey, MD

Professor of Oncology - Mayo Clinic College of Medicine

Consultant - Mayo Clinic Rochester

Rochester, Minnesota

Author has received grant research support from Bayer, Daiichi, Genentech, and F. Hoffman LaRoche. He has also been a consultant for Genentech, Hoffman La Roche, and Pfizer

Author indicates that he does plan to discuss unlabeled/investigational uses of commercial products.

David H. Henry, MD

Clinical Professor of Medicine and Vice Chair, Department of Medicine

University of Pennsylvania Health System

Philadelphia, Pennsylvania

Author has been on the speaker’s bureau for Amgen, Ortho Biotech, and Watson.

Author indicates that he does plan to discuss unlabeled/investigational uses of commercial products.

Ronald Natale, MD

Director, Lung Cancer Research Program

Samuel Oschin Comprehensive Cancer Institute

Cedars-Sinai Medical Center

Los Angeles, California

Author has received grant research support from Amgen, Eli Lilly, and Novartis. He has also been a consultant for Amgen.

Author indicates that he does plan to discuss unlabeled/investigational uses of commercial products.

Steven O'Day, MD

Clinical Associate Professor of Medicine - USC Keck School of Medicine

Chief of Research - The Angeles Clinic & Research Institute

Los Angeles, California

Author has received grant research support from Bristol-Myers Squibb, GlaxoSmithKline, and Hoffman LaRoche. He has been a consultant and or speaker for Bristol-Myers Squibb and a consultant for GlaxoSmithKline and Hoffman LaRoche.

Author indicates that he does plan to discuss unlabeled/investigational uses of commercial products.

Cary N. Robertson, MD

Associate Professor of Surgery, Division of Urology

Duke University Medical Center

Durham, North Carolina

Author has been a consultant and speaker for Ortho Biotech and a consultant for EDAP TMS, Endo-Pharma. He has also been a speaker for Aureon Laboratories.

Author indicates that he does not plan to discuss unlabeled/investigational uses of commercial products.

Alison T. Stopeck, MD

Associate Professor of Medicine - University of Arizona

Director, Clinical Breast Cancer Program - Arizona Cancer Center

Tucson, Arizona

Author has been a consultant and speaker for Amgen. She has also been a consultant for Novartis and a speaker for Genomic Health.

Author indicates that she does plan to discuss unlabeled/investigational uses of commercial products.

Target Audience

This activity has been developed for medical oncologists, hematologists, radiation oncologists, oncology nurses, and other healthcare providers related to the field.

Educational Needs

The volume of information emerging from cancer research challenges oncologists’ ability to translate evidence into clinical care. Assessments of clinical practice have shown that as many as 45% of patients do not receive evidence-based care and that as much as 25% of the care that patients do receive is unnecessary or potentially harmful. Studies of clinical oncology practices have found that application of evidenced-based care has the potential to improve patient outcomes and reduce mortality. Clinicians have an ongoing need for concise, evidence-based educational activities that can facilitate the integration of new information into clinical oncology practice. Responses to a recent educational needs survey showed that clinical oncology professionals place a high priority on remaining current with emerging data, integrating emerging data into clinical practice , and formulating evidence-based treatment plans that meet the individual patient needs.

1. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care, 2001; 39:1146-1154
2. 2. McGlynn E, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:-2635-2645.
3. 3. Canadian Cancer Control Strategy. Canadian strategy for cancer control. Draft synthesis report. Ottawa, Ontario:Canadian Cancer Control Strategy, 2001.

Learning Objectives

• After completing this educational activity, participants should be able to:
• Discuss recent developments related to integration of novel agents into the treatment of non-small cell lung cancer
• Describe the scientific rationale for use of PARP inhibitors to treat cancer
• Discuss outcomes of recent clinical trials of PARP inhibitors
• Recognize the role of bone-targeted therapy in clinical oncology practice
• Understand distinctions between bisphosphonates and RANK ligand inhibitors
• Describe recent developments in the treatment of melanoma
• Discuss novel therapies recently approved for treatment of advanced prostate cancer
• Describe recent clinical trial data related to Hodgkin disease and non-Hodgkin lymphoma
• Review current and emerging treatment options for gastrointestinal and colon cancer
• Appreciate differences between traditional and novel HER2-targeted agents

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Boston University School of Medicine and Global Academy for Medical Education, LLC, an Elsevier business. Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Boston University School of Medicine designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

---